Biophytis share surges 14.5% following treasury update
The Parisian biotech company benefits from a press release published this morning to soar on the stock exchange, in an almost stable Paris market. The rebound occurs as the stock has remained under pressure for several sessions, with a decline of nearly 41% over the past week.
A 14% jump driven by the publication of a reassuring liquidity update
Biophytis gains 14.31% during trading, at 0.0599 €, following the publication this morning of an update on its treasury situation. The company announces having 3.0 million euros in liquidity, following the exercise of the majority of its 2026 subscription warrants and a conversion of part of its debt into equity. This operation made it possible to reduce debt by more than 30%, and the biotech indicates it covers its financing needs until the first quarter of 2027. The rebound takes place in a globally neutral market context: the CAC 40 and SBF 120 both advance 0.09% during trading.
A stock below its 20-day moving average despite a quarter that tripled the price
The technical configuration remains mixed. The price of 0.0599 € is below the 20-day moving average (0.07 €, representing a gap of -14.43%), reflecting short-term momentum still unfavorable despite today's rebound. On the other hand, the stock remains well above its 50 and 200-day moving averages (both around 0.04 €), reflecting a gain of more than 210% over three months.
The RSI at 46 remains neutral, without a strong directional signal. The weekly performance (-40.95%) underscores the high volatility of the stock, whose monthly volatility level exceeds 46%. The next resistance level is at 0.13 €, more than double the current price.
